Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INCY

Incyte Corp

Mar 13 • 02:53PM ET

67.85

Dollar change +0.12
Percentage change 0.18	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO VB RSP SPY XBI IVV VO USMV VBK

Scroll to Statements

Index	S&P 500	P/E	250.18	EPS (ttm)	0.27	Insider Own	1.46%	Shs Outstand	193.43M	Perf Week	-3.20%
Market Cap	13.13B	Forward P/E	10.21	EPS next Y	6.64	Insider Trans	-1.65%	Shs Float	190.71M	Perf Month	2.29%
Income	32.62M	PEG	2.60	EPS next Q	1.01	Inst Own	95.40%	Short Float	3.07%	Perf Quarter	-5.91%
Sales	4.24B	P/S	3.10	EPS this Y	422.92%	Inst Trans	-0.08%	Short Ratio	3.47	Perf Half Y	7.48%
Book/sh	17.82	P/B	3.81	EPS next Y	18.06%	ROA	0.53%	Short Interest	5.85M	Perf Year	11.61%
Cash/sh	11.15	P/C	6.08	EPS next 5Y	96.29%	ROE	0.76%	52W Range	50.35 - 83.95	Perf YTD	-1.77%
Dividend Est.	-	P/FCF	52.72	EPS past 5Y	-40.36%	ROI	0.93%	52W High	-19.18%	Beta	0.85
Dividend TTM	-	Quick Ratio	1.94	Sales past 5Y	14.56%	Gross Margin	91.09%	52W Low	34.76%	ATR (14)	2.32
Dividend Ex-Date	-	Current Ratio	1.97	EPS Y/Y TTM	-88.32%	Oper. Margin	1.89%	RSI (14)	37.92	Volatility	4.07% 3.40%
Employees	2617	Debt/Eq	0.02	Sales Y/Y TTM	14.76%	Profit Margin	0.77%	Recom	2.30	Target Price	77.42
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	14.62%	Payout	0.00%	Rel Volume	0.41	Prev Close	67.73
Sales Surprise	3.39%	EPS Surprise	-5.06%	Sales Q/Q	16.32%	Earnings	Feb 10 BMO	Avg Volume	1.68M	Price	67.85
SMA20	-4.45%	SMA50	-5.27%	SMA200	0.30%	Trades		Volume	574,330	Change	0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100
Aug-03-22	Downgrade	Guggenheim	Buy → Neutral
Aug-03-22	Downgrade	Evercore ISI	Outperform → In-line	$90 → $78
Jul-28-22	Initiated	Wells Fargo	Equal Weight	$76

Show Previous Ratings

Mar-12-25 11:30AM	Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-11-25 08:48AM	Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss (Benzinga)
Mar-10-25 01:38PM	Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps (Benzinga)
Mar-08-25 01:00PM	Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study (PR Newswire)
09:01AM	Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting (Business Wire)
04:30PM	Loading…
Mar-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-25 02:31PM	Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-28-25 09:30AM	Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Feb-25-25 08:53AM	Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery (Insider Monkey)
Feb-21-25 07:20AM	Incyte and Genesis collaborate on small-molecule medicines (Pharmaceutical Technology)
Feb-20-25 08:00AM	Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration (Business Wire)
Feb-18-25 04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
03:00AM	Incyte Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
Feb-11-25 05:55PM	Analyst Report: Incyte Corporation (Morningstar Research)
02:04AM	Loading…
02:04AM	Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook (GuruFocus.com)
Feb-10-25 11:28PM	Q4 2024 Incyte Corp Earnings Call (Thomson Reuters StreetEvents) -7.86%
05:27PM	S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update (Investopedia)
04:43PM	Incyte Reports 2024 Financial Results and Outlines 2025 Projections (GuruFocus.com)
02:56PM	Why Incyte (INCY) Shares Are Plunging Today (StockStory)
02:47PM	Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short (Investopedia)
10:38AM	Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches (Benzinga)
09:30AM	Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Incyte (INCY) Q4 Earnings Miss Estimates (Zacks)
07:30AM	Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4 (StockStory)
07:23AM	Incyte: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones (Business Wire)
Feb-09-25 08:02AM	Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow (StockStory)
Feb-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.86%
Feb-05-25 09:15AM	Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
10:00AM	Loading…
Feb-03-25 10:00AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-21-25 08:00AM	Incyte to Report Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
Jan-15-25 05:34PM	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes (PR Newswire)
08:54AM	JP Morgan 2025: Incyte expects period of defining catalysts (Pharmaceutical Technology)
Jan-13-25 09:40AM	Has Incyte (INCY) Outpaced Other Medical Stocks This Year? (Zacks)
08:30AM	Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-08-25 06:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-20-24 07:20AM	Incyte price target raised to $70 from $68 at Wells Fargo (TipRanks)
Dec-17-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Dec-11-24 06:06PM	ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma (Clinical Trials Arena)
Dec-10-24 10:30AM	Incyte Late-Breaking Tafasitamab (Monjuvi) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Dec-09-24 04:46PM	Analyst Report: Incyte Corporation (Morningstar Research) -5.02%
Dec-07-24 07:30AM	Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (Business Wire)
Dec-06-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.02%
Nov-28-24 11:31AM	Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report? (Zacks)
Nov-26-24 04:10PM	Incyte Announces Updated Presentation Time for Upcoming Investor Conference (Business Wire)
Nov-25-24 10:09AM	Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting (Business Wire)
Nov-22-24 06:01AM	Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock (Insider Monkey)
Nov-20-24 04:31PM	Analyst Report: Incyte Corporation (Morningstar Research)
Nov-19-24 04:30PM	S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing (Investopedia) -8.33%
04:02PM	Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. (Investor's Business Daily)
12:41PM	Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study (Investopedia)
12:21PM	Incyte Is the S&P 500s Worst Performer Today. Whats Hitting the Stock. (Barrons.com)
12:18PM	Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges (Benzinga)
11:30AM	Incyte Faces Challenges but Remains Focused on Strategic Growth (GuruFocus.com)
06:13AM	Incyte sinks on setback for drugs acquired in $750M buyout (BioPharma Dive)
Nov-18-24 10:40PM	Analyst Report: Incyte Corporation (Morningstar Research)
04:30PM	Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs (Business Wire)
08:28AM	Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
Nov-16-24 10:06AM	Heres How Jakafis Patent Expiry Impacts Incyte Corporations (INCY) Growth Prospects (Insider Monkey)
Nov-15-24 07:05PM	Analyst Report: Incyte Corporation (Morningstar Research)
Nov-14-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Nov-07-24 07:22PM	Analyst Report: Incyte Corporation (Morningstar Research)
04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-24 06:02AM	Bank of America Turns Bullish on These 2 Lesser-Known Stocks (TipRanks)
Nov-05-24 04:32AM	Syndax agrees funding with Royalty Pharma for Niktimvo US sales (Pharmaceutical Technology)
Oct-30-24 04:37PM	Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock (Benzinga)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
03:03AM	Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:05AM	Q3 2024 Incyte Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-29-24 04:59PM	S&P 500 Gains and Losses Today: Ford Stock Falters as Earnings Miss the Mark (Investopedia) +12.04%
04:10PM	Incyte Breaks Out To 17-Month High As Jakafi Demand Surges (Investor's Business Daily)
12:23PM	Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted (GuruFocus.com)
12:07PM	Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura (Benzinga)
09:30AM	Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings (Zacks)
08:15AM	Incyte (INCY) Q3 Earnings Miss Estimates (Zacks)
07:13AM	Incyte: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Oct-24-24 02:03PM	Incyte Named One of Top 5 Companies on Science Magazines 2024 Top Employers List (Business Wire)
Oct-17-24 01:02PM	State Street Corp's Strategic Reduction in Incyte Corp Holdings (GuruFocus.com)
Oct-15-24 08:30AM	Knight Therapeutics Announces Approval of Minjuvi (tafasitamab) in Mexico (GlobeNewswire)
Oct-10-24 09:15AM	Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program (Business Wire)
Oct-08-24 08:00AM	Incyte to Report Third Quarter Financial Results (Business Wire)
Oct-07-24 11:08PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-03-24 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-25-24 07:00AM	Multiple Late-Breaking Data Presentations from Incytes Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress (Business Wire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-18-24 05:15PM	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease (PR Newswire)
02:44PM	Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets (Benzinga)
Sep-16-24 08:27PM	Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers (Investor's Business Daily)
Sep-14-24 12:45PM	Incytes CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer (Business Wire)
10:30AM	Incytes Retifanlimab (Zynyz) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium (Business Wire)
Sep-09-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-24 11:31AM	Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-21-24 11:40AM	Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 (Business Wire)
Aug-17-24 01:20AM	Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug (Zacks)
Aug-16-24 10:33AM	Armed with Phase III win, Incyte eyes label expansion for Monjuvi (Pharmaceutical Technology)
Aug-15-24 04:30PM	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi) in Relapsed or Refractory Follicular Lymphoma (Business Wire)
12:32PM	FDA greenlights Incyte and Syndaxs GvHD drug Niktimvo (Pharmaceutical Technology)
10:11AM	FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication (Benzinga)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Option Exercise	58.06	599	34,778	26,447	Mar 06 04:56 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Sale	69.99	599	41,924	25,848	Mar 06 04:56 PM
SHEILA DENTON	Officer	Mar 04 '25	Proposed Sale	69.99	599	41,924		Mar 04 05:12 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Option Exercise	58.06	9,574	555,866	39,917	Feb 28 06:34 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Sale	74.07	14,069	1,042,136	25,848	Feb 28 06:34 PM
SHEILA DENTON	Officer	Feb 26 '25	Proposed Sale	74.07	14,069	1,042,138		Feb 26 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 21 '25	Sale	72.69	12,352	897,867	66,967	Jan 22 04:05 PM
STEVEN STEIN	Officer	Jan 21 '25	Proposed Sale	72.69	12,352	897,906		Jan 21 04:03 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '24	Sale	70.64	650	45,916	23,962	Dec 17 12:37 PM
Tray Thomas	Principal Accounting Officer	Dec 16 '24	Sale	69.31	650	45,052	23,312	Dec 17 12:37 PM
THOMAS R TRAY	Officer	Dec 16 '24	Proposed Sale	69.31	650	45,052		Dec 16 04:04 PM
Iyengar Vijay K	EVP, GMAPPS	Nov 29 '24	Sale	75.38	6,043	455,544	30,658	Dec 03 12:52 PM
VIJAY IYENGAR	Officer	Nov 29 '24	Proposed Sale	75.39	6,043	455,555		Nov 29 01:28 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Option Exercise	70.03	3,680	257,719	61,722	Nov 08 12:48 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Sale	79.68	3,680	293,210	58,042	Nov 08 12:48 PM
BARRY FLANNELLY	Officer	Nov 06 '24	Proposed Sale	79.68	3,680	293,210		Nov 06 04:15 PM
Tray Thomas	Principal Accounting Officer	Sep 12 '24	Sale	62.94	572	36,002	24,825	Sep 16 01:25 PM
Tray Thomas	Principal Accounting Officer	Sep 13 '24	Sale	63.37	382	24,207	24,443	Sep 16 01:25 PM
Dickinson Jonathan Elliott	EVP, General Manager, Europe	Sep 12 '24	Sale	62.36	8,450	526,948	36,390	Sep 16 01:24 PM
THOMAS R TRAY	Officer	Sep 13 '24	Proposed Sale	63.37	382	24,207		Sep 13 04:06 PM
JONATHAN ELLIOTT DICKINSON	Officer	Sep 12 '24	Proposed Sale	62.36	8,450	526,930		Sep 12 04:17 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 12 '24	Sale	60.63	11,608	703,793	90,011	Aug 14 03:37 PM
STEVEN STEIN	Officer	Aug 12 '24	Proposed Sale	60.63	11,608	703,771		Aug 12 04:39 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 25 '24	Sale	70.00	15,571	1,089,970	36,701	Jul 29 03:50 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '24	Sale	64.19	1,306	83,832	58,042	Jul 17 12:24 PM
Flannelly Barry P	EVP & General Manager US	Jul 09 '24	Sale	60.00	8,148	488,880	50,534	Jul 11 12:35 PM
Flannelly Barry P	EVP & General Manager US	Jun 12 '24	Sale	60.00	19,164	1,149,840	66,377	Jun 14 12:17 PM
Tray Thomas	Principal Accounting Officer	Jun 06 '24	Sale	58.91	1,093	64,389	21,634	Jun 10 12:25 PM
BAKER BROS. ADVISORS LP	Director	May 07 '24	Option Exercise	49.01	30,000	1,470,300	33,462,981	May 09 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp

Upgrade your FINVIZ experience